A detailed history of Prudential PLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Prudential PLC holds 58,075 shares of HALO stock, worth $3.54 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
58,075
Previous 56,262 3.22%
Holding current value
$3.54 Million
Previous $3.22 Million 13.74%
% of portfolio
0.01%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$42.57 - $61.09 $77,179 - $110,756
1,813 Added 3.22%
58,075 $2.78 Million
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $735,847 - $924,040
14,344 Added 34.22%
56,262 $3.22 Million
Q1 2024

May 14, 2024

BUY
$33.68 - $41.95 $274,323 - $341,682
8,145 Added 24.12%
41,918 $1.71 Million
Q4 2023

Feb 13, 2024

BUY
$33.32 - $42.1 $1.13 Million - $1.42 Million
33,773 New
33,773 $1.25 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.49B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Prudential PLC Portfolio

Follow Prudential PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential PLC, based on Form 13F filings with the SEC.

News

Stay updated on Prudential PLC with notifications on news.